Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PYC TherapeuticsASX:PYC +1.49%31 EV-to-OCF is -23.61 as of Aug. 02, 2026. GuruFocus rates ASX:PYC with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 1,410 Biotechnology companies, PYC Therapeutics ranks better than 83.26% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, PYC Therapeutics's Enterprise Value is A$1,552.25 Mil.
PYC Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was A$-65.75 Mil. Therefore, PYC Therapeutics's EV-to-OCF for today is -23.61.
The historical rank and industry rank for PYC Therapeutics's EV-to-OCF or its related term are showing as below:
ASX:PYC'
s EV-to-OCF Range Over the Past 10 Years
Min: -209.25 Med: -71.31 Max: -6.19
Current: -23.01
During the past 13 years, the highest EV-to-OCF of PYC Therapeutics was -6.19. The lowest was -209.25. And the median was -71.31.
ASX:PYC's EV-to-OCF is ranked better than 83.26% of 1410
companies
in the Biotechnology industry
Industry Median: -3.23
vs ASX:PYC: -23.01
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
PYC Therapeutics's PE Ratio (TTM) for today is calculated as:
PYC Therapeutics's share price for today is A$1.70.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PYC Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.083.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
PYC Therapeutics EV-to-OCF Related Terms
PYC Therapeutics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for PYC Therapeutics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, PYC Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PYC Therapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PYC Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where PYC Therapeutics's EV-to-OCF falls into.
PYC Therapeutics's current Enterprise Value is A$1,552.25 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PYC Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was A$-65.75 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PYC Therapeutics (ASX:PYC) has a EV-to-OCF of -23.61 as of Aug. 02, 2026. According to the industry distribution chart, PYC Therapeutics ranks #236 out of 1410 companies in the Biotechnology industry, placing it in the top 16.7%.
Is PYC Therapeutics' EV-to-OCF too high?
PYC Therapeutics' current EV-to-OCF is -23.61. Based on the distribution chart, PYC Therapeutics ranks #236 out of 1410 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, PYC Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does PYC Therapeutics' EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, PYC Therapeutics ranks #236 out of 1410 companies for EV-to-OCF. This places PYC Therapeutics in the top 17% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. PYC Therapeutics's current EV-to-OCF is -23.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PYC Therapeutics stock overvalued right now?
PYC Therapeutics (ASX:PYC) has a current EV-to-OCF of -23.61. The current EV-to-OCF is -23.61. PYC Therapeutics' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For PYC Therapeutics (ASX:PYC), the current EV-to-OCF is -23.61 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PYC Therapeutics Ltd is an RNA therapeutics drug development company, leveraging a proprietary delivery platform to solve the challenges in RNA therapeutics - safe and effective delivery of the drug inside the cell. The company's principal business activity is of of drug development and progressing the company's drug pipeline through preclinical and clinical development. Geographically, it operates only in Australia.
31GF Score
Get the complete analysis for ASX:PYC
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:PYC has been successfully added to your 
